scholarly journals Low Visceral Fat Content Is a Negative Predictive Marker for Bevacizumab in Metastatic Colorectal Cancer

2018 ◽  
Vol 38 (1) ◽  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Visceral Fat ◽  
Predictive Marker ◽  
Fat Content ◽  
Visceral Fat Content

scholarly journals The SLICE study: The prognostic role of visceral fat in metastatic colorectal cancer

2018 ◽  
Vol 29 ◽  
pp. viii193
Author(s):  
D. Basile ◽  
C. Lisanti ◽  
M. Borghi ◽  
M. Bartoletti ◽  
L. Gerratana ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Visceral Fat ◽  
Prognostic Role

The relationship between thyroid hormone and lipid metabolism/body fat content in euthyroid male patients with type 2 diabetes mellitus in China: A cross-sectional study

2020 ◽  
Author(s):  
Xia Sun ◽  
Liping Chen ◽  
Rongzhen Wu ◽  
Dan Zhang ◽  
Yinhui He
Keyword(s):  
Body Fat ◽  
Visceral Fat ◽  
Fat Content ◽  
Body Fat Percentage ◽  
Fat Percentage ◽  
Body Fat Content ◽  
Male Patients ◽  
The Relationship ◽  
Visceral Fat Content

Abstract Background: This study compared the relationship between thyroid hormones and lipid metabolism/body fat content in euthyroid male patients with type 2 diabetes mellitus (T2DM) in China. Methods: A total of 64 male patients who were diagnosed as T2DM and 64 non-diabetic males who underwent health examination were matched according to age at a 1:1 ratio. Results: The 32 subjects in each sub-group showed differences in age, body mass index (BMI), mean arterial pressure, waist circumference, visceral fat content, body fat percentage, HbA1c, HOMA-IR, FT3, TSH, HDL-c, adiponectin, leptin, visfatin and TNF-α (all P < 0.05). In the overall population, FT3 was positively correlated with body fat percentage (r=0.21, P=0.02), and negatively correlated with HOMA-IR (r=-0.18, P=0.04) and visfatin (r=-0.47, P <0.01); TSH was positively correlated with body fat percentage (r=0.23, P=0.01). In the T2DM-OB group FT3 was positively correlated with BMI (r=0.45, P <0.05), visceral fat content (r=0.50, P <0.05), and body fat percentage (r=0.44, P <0.05); FT4 was positively correlated with visceral fat content (r=0.38, P <0.05); and TSH was positively correlated with HOMA-IR (r=0.39, P <0.05). Conclusion: TSH increased in obese people and FT3 was lower in patients with T2DM.

scholarly journals 169P Serum CA19-9 response is an early predictive marker for the efficacy of regorafenib in refractory metastatic colorectal cancer

2015 ◽  
Vol 26 ◽  
pp. ix42
Author(s):  
A. Komori ◽  
H. Taniguchi ◽  
Y. Kito ◽  
S. Hamauchi ◽  
T. Masuishi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Predictive Marker

Visceral fat as a predictive marker of response to bevacizumab-based treatment in metastatic colorectal cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e14665-e14665
Author(s):  
Yuji Miyamoto ◽  
Yasuo Sakamoto ◽  
Masayuki Watanabe ◽  
Hideo Baba
Keyword(s):  
Colorectal Cancer ◽  
Visceral Fat ◽  
Subcutaneous Fat ◽  
Predictive Marker ◽  
Line Treatment ◽  
First Line ◽  
Chemotherapy Group ◽  
Fat Volume ◽  
First Line Treatment

e14665 Background: A large amount of visceral adipose tissue might be correlated with high VEGF levels and with resistance to bevacizumab-based regimens in metastasic colorectal cancer (mCRC). The aim is to evaluate that abdominal obesity can be a predictive marker of response to bevacizumab-based therapy in mCRC. Methods: From January 2005 to December 2010, we performed a retrospective analysis of 74 consecutive patients with mCRC received bevacizumab-based first line treatment. Pretreatment CT was used to measure visceral fat volume (VFV), subcutaneous fat volume (SFV) an waist circumference (WC) in 74 patients with mCRC who received bevacizumab-based first-line treatment (bevacizumab group, n=37) or chemotherapy alone (chemotherapy group, n=37). Associations linkingVFV, SFV and WC to tumor response, progression free survival (PFS) and overall survival (OS) were evaluated. For all analyses, VFV, SFV and WC were dichotomized using the median as the cut-off point. Results: In the bevacizumab group, median follow-up lasted for 25 months (7-47). VFV, SFV and WC values were not associated with response or OS. PFS was shorter in patients with high VFV (12.8 vs 7.7 months; p=0.04). By multivariate analysis, high VFA was independently associated with PFS (HR=4.32, p=0.045). In the chemotherapy group, median follow-up lasted for 26 months (2-68). VFV, SFV and WC were not associated with response, PFS or OS. Conclusions: Visceral fat volume plays a role of predictive marker of PFS to bevacizumab-based therapy for Japanese patients with mCRC.

Soluble CD87 (s-uPAR) predicts bevacizumab-based first line treatment of metastatic colorectal cancer (mCRC): Results from a prospective multi-center study.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 604-604 ◽  
Author(s):  
Matthias Unseld ◽  
Gabriele Kornek ◽  
Andreas Gleiss ◽  
Svitlana Demyantes ◽  
Jost Schwarzwald ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Predictive Marker ◽  
Endothelial Cell Migration ◽  
Migration And Invasion ◽  
Induction Treatment ◽  
Line Treatment ◽  
First Line ◽  
Urokinase Plasminogen Activator Receptor ◽  
First Line Treatment

604 Background: Bevacizumab-combined chemotherapy is well established in the induction treatment of metastatic colorectal cancer (mCRC). Despite tremendous efforts, no valid predictive marker for anti-VEGF treatment has so far been defined. CD87, the urokinase plasminogen activator receptor (uPAR), is centrally regulating VEGF-induced angiogenesis via adapting endothelial cell migration and invasion (Unseld et al.; ThrombHaem,2015, Brunner et al.; Blood 2011, Prager et al; Blood 2009; Prager et al; Blood 2004). Preoperative plasma s-uPAR levels were shown to independently predicted survival of patients resectable colorectal cancer. This study aimed to identify any prognostic or predictive value of s-uPAR in front-line bevacizumab-treated mCRC patients. Methods: In this prospective multi-center trial (NCT02119026), patients were either treated with bevacizumab plus FOLFOX or bevacizumab plus FOLFIRI. Baseline s-uPAR levels were assessed in 80 patients (40 ea. group) using respective CE-certified electro-chemiluminescence immunoassay (ECLIA). Biomarkers were explored using Kaplan-Meier curves and were log transformed for survival analysis by Cox proportional hazards models. All P values reported are two-sided. Results: Data from eighty patients were available for analysis. Progression free survival (PFS) and overall survival (OS) were assessed. Data indicate significance for the angiogenic biomarker uPAR to determine prognostic (HR = 3.06, CI 1.45 - 6.53, p = 0.003) and predictive (HR = 3.41, CI 2.03 - 5.74, p < 0.001) value in the treatment of Bevacizumab. Conclusions: This is the first prospective analysis of baseline s-uPAR. High baseline-s-uPAR levels were an independent predictive marker for worse bevacizumab-based first-line treatment response.

Plasma VEGF-A (pVEGF-A) level in efficacy analysis of metastatic colorectal cancer patients (mCRC) treated with mFOLFOX6/XELOX plus bevacizumab (BV) (WJOG7612GTR).

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 699-699
Author(s):  
Wataru Okamoto ◽  
Akitaka Makiyama ◽  
Yoshiyuki Yamamoto ◽  
Kohei Shitara ◽  
Tadamichi Denda ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Proportional Hazards ◽  
Proportional Hazards Model ◽  
Progression Free Survival ◽  
Predictive Marker ◽  
Cox Proportional Hazards ◽  
Cox Proportional Hazards Model ◽  
Enzyme Linked Immunosorbent Assay ◽  
Negative Results

699 Background: Plasma levels of VEGF-A short isoforms (VEGF-A110 and -A121) measured by immunological multiparametric chip technique (IMPACT) were reported to be associated with clinical benefits from bevacizumab (BV) in advanced gastric and pancreatic cancer but not in metastatic colorectal cancer (mCRC). Negative results in mCRC studies might be caused by different sample handling: citrate instead of EDTA and repetition of freeze/thaw. Methods: Blood samples were collected in EDTA before the first-line treatment with BV+mFOLFOX6 or +XELOX for mCRC. Plasma samples were analyzed at Roche Diagnostics Ltd. (Penzberg, Germany) using IMPACT-2 (Roche proprietary multiplex enzyme-linked immunosorbent assay platform). A median value of pVEGF-A was used as a cut-off point to categorize patients (pts) into the low and high pVEGF-A groups. Progression free survival (PFS) and overall survival (OS) between the low and high pVEGF-A groups were compared, using Cox proportional hazards model. We hypothesized that BV-containing treatment extend shorter PFS of pts with high pVEGF-A to that with low pVEGF-A, and estimated a threshold hazard ratio (HR) between them as below 1.15. Results: Among 102 pts enrolled between January 2014 and April 2015, 100 (53 BV+mFOLFOX6 and 47 BV+XELOX) were eligible. Median PFS was 11.4 months [95% CI, 9.5-13.0] and response rate was 64.6 % [range, 53.3-74.9]. pVEGF-A was measured in 97 pts and the median value was 36.8 pg/ml [range, 6.5- 262.2]. The hazard ratios of PFS and OS between the high and low pVEGF-A groups were 1.23 [95%CI, 0.76-1.97, p = 0.40] and 2.47 [95%CI, 1.14-5.36, p = 0.02], respectively. Conclusions: mCRC pts with high pVEGF-A showed shorter PFS than those with low pVEGF-A beyond the predefined threshold (HR 1.15) in BV-containing chemotherapy, suggesting that pVEGF-A could not be a predictive marker for BV efficacy. Clinical trial information: UMIN000012442.

Visceral Fat Content Correlates with Retroperitoneal Soft Tissue Sarcoma (STS) Local Recurrence and Survival

2015 ◽  
Vol 39 (8) ◽  
pp. 1895-1901 ◽  
Author(s):  
Michail Papoulas ◽  
Roi Weiser ◽  
Galia Rosen ◽  
Fabian Gerstenhaber ◽  
Ofer Merimsky ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Local Recurrence ◽  
Soft Tissue Sarcoma ◽  
Visceral Fat ◽  
Fat Content ◽  
Visceral Fat Content ◽  
Retroperitoneal Soft Tissue Sarcoma
Sign in / Sign up

Export Citation Format

Share Document